Trial · NCT07884955
Comparing Inclisiran Versus Statin for Primary Aldosteronism
NCT07884955, Not applicable, Recruiting, Third Military Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparing Inclisiran Versus Statin for Primary Aldosteronism. Trials, record NCT07884955. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884955
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing Inclisiran Versus Statin for Primary Aldosteronism
- NCT number
- NCT07884955
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Third Military Medical University
- Conditions
- Primary Aldosteronism
- Interventions
- inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug), Amlodipine besylate
- First posted
- 2026-10-21
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in plasma aldosterone level | 24 weeks after randomization | |
| Secondary | Change from baseline in systolic and diastolic blood pressure | 24 weeks after randomization | |
| Secondary | Change from baseline in plasma renin concentration | 24 weeks after randomization | |
| Secondary | Change from baseline in 24-hour urinary aldosterone | 24 weeks after randomization | |
| Secondary | Change from baseline in serum potassium level | 24 weeks after randomization | |
| Secondary | Change from baseline in plasma lipid | 24 weeks after randomization | |
| Secondary | Change from baseline in glucose | 24 weeks after randomization |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884955
GET https://conductscience.org/api/trials/v1/NCT07884955/registered